Search

Displaying results 1611 - 1620 of 1994 in total
  1. Drug

    KP1237

    go.drugbank.com/drugs/DB18401
    Experimental

    KP1237 is a antibody-redirecting molecule composed of two binding sites (a CD38 binder and a universal antibody binding terminus binder) connected by a linker chain.

  2. Drug

    SPC2968

    go.drugbank.com/drugs/DB06351
    Investigational

    SPC2968 is a synthetic antisense oligodeoxynucleotide targeting hypoxia-inducible factor-1alpha (HIF-1alpha). It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic ...

  3. Drug

    RDEA806

    go.drugbank.com/drugs/DB05228
    Investigational

    RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.

  4. Drug

    Ornithine

    go.drugbank.com/drugs/DB00129
    ApprovedInvestigationalNutraceutical

    Produced during the urea cycle, ornithine is an amino acid produced from the splitting off of urea from arginine. L-Ornithine allows for the disposal of excess nitrogen and acts as a precursor of citrulline and arginine.

    Mixtures: Primene 10% pur - Infusionslösung
  5. Drug

    Q-Derp1

    go.drugbank.com/drugs/DB05857
    Experimental

    Derp1 is the dominant allergic protein found in dust mite feces.

  6. Drug

    Clinafloxacin

    go.drugbank.com/drugs/DB14025
    Experimental

    However, its approval and release have been halted due to the presence of serious side effects.

  7. Drug

    Adermastat

    go.drugbank.com/drugs/DB28906
    Investigational

    Adermastat is under investigation in clinical trial NCT03858686 (The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.).

  8. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  9. Drug

    Catridecacog

    go.drugbank.com/drugs/DB09310
    Approved

    When activated by thrombin at the site of injury, the FXIII A2B2 pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. … In these patients, activated rFXIII has been shown to increase the mechanical strength of fibrin clots, slow down fibrinolysis, and to enhance platelet adhesion to the site of injury.

  10. Drug

    Indium In-111 oxyquinoline

    go.drugbank.com/drugs/DB09473
    Approved

    The degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process.